Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department.
Current research lines include the optimization of chemotherapy in early-stage disease, evaluation of new agents and therapies, research into novel pharmacogenomic approaches, the integration of immunotherapeutic approaches in the treatment of lung cancer patients, and the elucidation of potential mechanisms of resistance to tyrosine-kinase inhibitors.